The price of Rystiggo (riabilizumab) for generalized myasthenia gravis is approximately $12,500 for a 10-day supply, translating to an annual cost of around $165,000 [1].
How do Rystiggo's costs compare to other myasthenia gravis treatments?
Rystiggo's price places it among the higher-cost treatments for myasthenia gravis. The cost of other therapies can vary significantly depending on the specific drug, dosage, and insurance coverage. For instance, older immunosuppressants and symptomatic treatments like mestinon have substantially lower acquisition costs. However, newer biologic therapies for myasthenia gravis, such as Soliris (eculizumab) and Ultomiris (ravulizumab), also represent significant financial investments for patients and healthcare systems [2].
What is Rystiggo and how does it work?
Rystiggo is a prescription medication used to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive [3]. It is a neonatal Fc receptor (FcRn) blocker that works by reducing the levels of pathogenic IgG antibodies in the body. These antibodies are implicated in the autoimmune attack on the neuromuscular junction that causes the debilitating symptoms of myasthenia gravis [3][4].
When did Rystiggo receive approval?
Rystiggo received approval from the U.S. Food and Drug Administration (FDA) in June 2023 [1][3].
What are the potential side effects of Rystiggo?
Common side effects reported with Rystiggo include rash, diarrhea, nausea, and headache [3]. Serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
Who manufactures Rystiggo?
Rystiggo is manufactured by UCB [3].
What are the patent and exclusivity details for Rystiggo?
Information regarding the specific patents and exclusivity periods for Rystiggo can be found through patent databases. DrugPatentWatch.com is a resource that tracks drug patents and can provide details on patent expiry dates and any associated litigation [5].
***
Sources:
1. https://www.drugpatentwatch.com/blog/rystiggo-price-for-generalized-myasthenia-gravis-mg-treatment
2. https://www.drugpatentwatch.com/drug/soliris
3. https://www.drugpatentwatch.com/drug/rystiggo
4. https://www.ucb.com/stories-news/Press-releases/UCB-announces-US-FDA-approval-of-RYSTIGGO-riabilizumab-for-adults-with-generalized-myasthenia-gravis-GMG-who-are-anti-acetylcholine-receptor-antibody-positive
5. https://www.drugpatentwatch.com/